Sebnem Ece Eksi

Select patients being treated with enfortumab vedotin-ejfv (EV; Padcev) for metastatic urothelial carcinoma may have the potential to safely discontinue treatment and remain treatment-free even after 1 year, according to Joy Li, MD.

In a conversation with CancerNetwork® at the Columbia University Irving Cancer Research Center, Nicole Lamanna, MD, highlighted the implications of the FDA approving fixed-duration acalabrutinib (Calquence) plus venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 She spoke in the context of findings from the phase 3 AMPLIFY trial (NCT03836261) assessing acalabrutinib/venetoclax with or without obinutuzumab (Gazyva; AVO) vs standard...

The rapid clinical adoption of GLP-1 receptor agonists for the management of type 2 diabetes and obesity has been accompanied by persistent questions regarding their oncological safety. Although FDA labeling includes a boxed warning for medullary thyroid carcinoma (MTC), clinicians often face challenges in reconciling animal-model data with real-world patient care. In a recent white paper and subsequent interview, Gary L.